Differentiation of B cells from uncommitted hematopoietic progenitors to antibody-producing plasma cells is a key process in the adaptive immune response. This differentiation is regulated through the coordinated expression of transcription factors along with a wave of epigenetic modulation in the germinal center [1] [2] [3] , where genes encoding immunoglobulins are somatically altered to optimize antibody affinity and avidity. The B cell lymphomas most common in childhood (Burkitt lymphoma/leukemia) and adulthood (diffuse large B cell lymphoma (DLBCL) and follicular lymphoma) are presumed to derive from or resemble germinal center B cells. They all show molecular features of germinal center B cells, with the mutational mechanisms active in the germinal center, such as somatic hypermutation, contributing to pathogenesis. Whereas DLBCL is heterogeneous with regard to the genetic alterations and gene expression patterns of tumor cells, Burkitt lymphoma and, to a considerable extent, also follicular lymphoma are much more homogenous lymphoma subtypes 4, 5 . Burkitt lymphoma is almost invariably associated with an IG-MYC chromosomal translocation, involving juxtaposition of the MYC oncogene encoding a transcription factor with one of the three immunoglobulin loci. The vast majority of follicular lymphomas, particularly those of grade 1 or 2, carry t(14;18)(q32;q21) chromosomal translocations juxtaposing the BCL2 oncogene mostly with the IGH locus (encoding immunoglobulin heavy chain) 6 . These lymphoma subtypes also display a different spectrum of secondary changes, with, for example, mutations in cell cycle regulators and in the ID3-TCF3 transcription factor complex being highly prevalent in Burkitt lymphoma [7] [8] [9] . This deregulation of particular transcription factors in Burkitt lymphoma and the DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control recurrent mutations in chromatin modifiers such as CREBBP, MEF2B, EZH2 and KMT2D found in follicular lymphoma indicate that lymphoma pathogenesis involves alterations in physiological epigenetic modulation [10] [11] [12] [13] [14] .
Clinically, patients affected with Burkitt lymphoma are significantly younger at diagnosis than those affected with follicular lymphoma. Moreover, Burkitt lymphoma shows a much higher proliferation rate and, thus, greater clinical aggressiveness than follicular lymphoma, which is a more indolent disease. Intriguingly, despite these considerable differences, both Burkitt lymphoma and follicular lymphoma are presumed to derive from the very same cell compartment of the human body, the germinal center B cell. Physiologically, normal germinal center B cells oscillate between the centroblast state predominant in the dark zone of a germinal center and the centrocyte state predominant in the light zone of the germinal center. Burkitt lymphoma and follicular lymphoma cells have been proposed to be 'frozen' in these functional states, with Burkitt lymphoma resembling the dark-zone germinal center B cell state and follicular lymphoma resembling the light-zone germinal center B cell state 15 . This offers the unique opportunity to study the epigenomic architecture of two neoplasms derived from the same cell of origin but showing considerably divergent genomic evolution.
RESULTS

Burkitt and follicular lymphomas show genome-wide hypomethylation
To better understand the relationship between epigenomic architecture, genetic alterations and phenotype in both germinal center B cell lymphoma subtypes, we performed whole-genome bisulfite sequencing (WGBS) and transcriptome sequencing of 13 IG-MYC translocation-positive Burkitt lymphoma samples and nine BCL2 translocation-positive follicular lymphoma samples (including eight follicular lymphomas falling in grade 1 or 2 and one follicular lymphoma classified as grade 3a/DLBCL). As a reference, FACS-sorted germinal center B cells from the non-neoplastic tonsils of four donors were analyzed in parallel. The source of the sample material, as well as clinical follow-up for all patients, is summarized in Supplementary  Table 1 . In total, 25 billion read pairs, with at least 0.7 billion read pairs per sample, were obtained in the WGBS analysis. On average, 92% of reads successfully mapped to the reference genome 16 , resulting in a mean coverage of 54× (Supplementary Table 2 ). The methylation rates called from the sequencing data showed excellent correlation with the β values obtained from Illumina HumanMethylation450K BeadChip analysis (Supplementary Table 3 ) for the same samples (mean R 2 = 0.921; Supplementary Fig. 1 ). For transcriptome sequencing, an average of 150 million reads were obtained per case, of which 94.5% mapped to the human genome (Supplementary Table 4 ). Our analyses were complemented by 30× whole-genome sequencing of tumors and matched controls from the same patients and the germinal center B cell populations, as well as eight additional Burkitt lymphomas (Supplementary Table 5) .
Analysis of average genome-wide CpG methylation showed all lymphoma entities to be hypomethylated in comparison to nonneoplastic germinal center B cells (Fig. 1a) . However, considerable differences could be seen in the extent and variability of DNA methylation between the Burkitt lymphoma and follicular lymphoma groups, despite their common germinal center B cell derivation (Fig. 1b) . In addition to global hypomethylation, considerable gains in DNA methylation were observed in Burkitt lymphoma and follicular lymphoma samples at CpGs with low-level methylation in germinal center B cells (methylation <0.3; Fig. 1c) . To determine whether DNA methylation patterns varied between genome segments with different functions, we compared methylation differences (averages of Burkitt lymphomas and follicular lymphomas versus germinal center B cells) for 15 chromatin states (Supplementary Table 6 ) defined in the GM12878 lymphoblastoid cell line, which is representative of non-neoplastic mature B cells 17 . For most chromatin states, individual segments showed either hyper-or hypomethylation largely neutralizing each other in the global analysis. However, changes in heterochromatin were mostly unidirectional, resulting in the greatest relative reduction in DNA methylation levels of any chromatin segment in the lymphoma samples. In stark contrast, poised promoters showed the strongest but a nevertheless small increase in DNA methylation levels at a global level (Fig. 1d) . In line with recent reports 18 , the observed small gains in poised promoter methylation were at times associated with increases in RNA expression of the associated genes in Burkitt lymphoma and follicular lymphoma samples ( Fig. 1e and Supplementary Fig. 2 ).
DNA methylation downstream of promoters correlates with gene expression
Gene-centered analysis, including coding and noncoding genes, showed increased levels of gene body methylation for highly expressed genes, which returned to background levels at transcription end sites (TESs). High transcription levels typically were associated with the presence of large hypomethylated regions downstream of transcription start sites (TSSs), suggesting regulatory relevance for these regions ( Fig. 2a and Supplementary Fig. 3 ). We applied an unbiased circular binary segmentation (CBS) approach to our entire WGBS data set, identifying 90,350 differentially methylated regions (DMRs) with ten or more CpGs between Burkitt lymphoma, follicular lymphoma and germinal center B cell controls. These DMRs included 27,607 and 36,775 DMRs between normal germinal center B cells and the follicular lymphoma and Burkitt lymphoma groups, respectively (Supplementary Table 7 ). The great majority of DMRs were located within transcribed regions (between TSSs and TESs) rather than in promoter regions (1,500-nt regions upstream of TSSs) or intergenic regions (Fig. 2b) , with strong enrichment of DMRs immediately downstream of TSSs (Fig. 2c) , analogous to the 'promoter downstream correlated regions' recently described in medulloblastoma 19 . No substantial differences in size were observed between intra-and intergenic DMRs (Supplementary Fig. 4) .
To define the role of these potential regulatory regions in Burkitt lymphoma and follicular lymphoma, we correlated the methylation levels of intragenic DMRs (contained in the transcribed regions and up to 1,500 bp upstream of the TSS) with the expression levels of the associated genes containing these DMRs. Forty percent of the intragenic DMRs showed significant (P < 0.05) correlations between methylation and RNA expression (Fig. 2d) , with the majority (64%) showing negative correlation ( Fig. 2e and Supplementary Table 8) . Overall, 85% of correlating DMRs (cDMRs) were located downstream of a TSS. Negatively and positively correlating DMRs did not differ in size; however, the former were highly enriched downstream of a TSS, whereas the latter were more evenly distributed across the gene body (Supplementary Fig. 4) . Examples of negatively correlating DMRs are shown in Supplementary Figure 5 . To ascertain the biological relevance of cDMR methylation, genes that previously had been reported as preferentially expressed in B cells of the dark zone or light zone of the germinal center 15 were examined; around 22% of dark zone-and 28% of light zone-specific genes possessed cDMRs. Dark zone-specific genes were predominantly hypomethylated and upregulated in Burkitt lymphoma, whereas they were hypermethylated A r t i c l e s and downregulated in follicular lymphoma (P < 0.001, Fisher's exact test; Fig. 2f,g ); light zone-specific genes showed the opposite pattern (P < 0.001, Fisher's exact test; Fig. 2f,h ). These data are in line with the view that the majority of Burkitt lymphomas are frozen in the dark-zone cell state, whereas the majority of follicular lymphomas are frozen in the light-zone cell state. Moreover, they suggest that methylation at cDMRs could act to fix the otherwise physiologically transient functional states of dark-zone and light-zone B cells in Burkitt lymphoma and follicular lymphoma samples, respectively. Examples include high expression of TCF3 and SMARCA4, which are more highly expressed in dark-zone than in light-zone B cells and in Burkitt lymphoma than in follicular lymphoma, as well as NFKB2 and TNFAIP3, showing the opposite expression pattern (Supplementary Fig. 6 ).
Differential methylation is common in key pathways in Burkitt lymphoma
The observed association between light zone-and dark zone-specific gene expression prompted us to more fully evaluate cDMR involvement in differential gene expression between Burkitt lymphoma and follicular lymphoma. Ingenuity Pathway Analysis (IPA) was performed on the basis of (i) all genes differentially expressed in Burkitt lymphoma and follicular lymphoma and (ii) the subset of differentially expressed genes with negatively correlating DMRs. Genes with positive correlations of methylation and expression were used as a negative control. The first gene set identified 60 pathways showing significant (P < 0.05) enrichment of differentially expressed genes; these were assigned scores indicating pathway activation (Supplementary Table 9 ). Analysis of genes with negatively correlating DMRs identified 58 of the 60 pathways, all with comparable ratios of gene enrichment and activation scores. Pathway analysis based on positively correlating DMRs identified significantly fewer pathways (17/60; P < 0.001, Fisher's exact test). These data strongly indicate that modulation of DNA methylation levels at negatively correlating DMRs is a common mechanism in the regulation of differential gene expression in Burkitt lymphoma and follicular lymphoma. Next, we sought to define the molecular mechanisms deregulated by DNA methylation, particularly in Burkitt lymphoma using follicular lymphoma as a contrasting group. This was achieved by directly comparing Burkitt lymphoma with follicular lymphoma rather than with germinal center B cells, as the latter analysis would have been underpowered and potentially biased owing to the smaller number of germinal center B cell samples available (n = 3). We identified 23 pathways with IPA that were differentially activated in Burkitt lymphoma and follicular lymphoma (Supplementary Table 10 ). To determine the directions of the gene expression changes in these activated pathways relative to germinal center B cell controls, we visualized gene expression in Burkitt lymphoma, follicular lymphoma and germinal center B cells for all 23 pathways (Supplementary Fig. 7 ). Gene ontology analysis of genes that were specifically downregulated in Burkitt lymphoma or follicular lymphoma in the 23 pathways identified suppression of processes related to inflammation and immunity in Burkitt lymphoma and cell cycle and DNA repair in follicular lymphoma ( Supplementary Fig. 8 ). Remarkably, one of the few genes that, relative to germinal center B cells, were upregulated in Burkitt lymphoma and downregulated in follicular lymphoma was IGF2BP1 (Supplementary Fig. 9 ), encoding an RNA-binding protein that stabilizes MYC 20 , underscoring its central importance in germinal center B cell lymphoma biology.
Detailed pathway-based analyses showed, for example, that DNA methylation was significantly associated with the downregulation of nuclear factor (NF)-κB signaling and the upregulation of cell cycle control genes in Burkitt lymphoma (Supplementary Figs. 10 and 11), concurrent with the proliferation rates of close to 100% Table 1) and consistent with previous reports on the molecular pathogenesis of Burkitt lymphoma [7] [8] [9] 21, 22 . The observed aberrant signaling was linked to differential methylation of key pathway genes in Burkitt lymphoma, including hypermethylation and downregulation of JAK3 and STAT3 (ref. 7) (Fig. 2h-j) , in line with low JAK-STAT pathway activity in Burkitt lymphoma. Another example of differential methylation for key regulatory genes in Burkitt lymphoma was hypomethylation and overexpression of the transcription factor TCF3 (Fig. 2k-m) . Remarkably, the TCF3 gene even harbored two cDMRs, of which cDMR1 contains a TCF3-binding site that is occupied in B cells 17 , suggesting the possibility of a positive feedback loop amplifying TCF3 transcription (Fig. 2k,l) . Analysis of published TCF3 chromatin immunoprecipitation and sequencing (ChIP-seq) data from the Burkitt lymphoma cell lines BL-41 and NAMALWA 9 confirmed TCF3 binding within cDMR1 that overlapped a common TCF3 binding motif, and the methylation levels of the CpGs surrounding this motif were inversely correlated with TCF3 expression in a larger set of 39 samples (Supplementary Fig. 12 ). These results indicate that, in addition to mutational mechanisms 8, 9, 22 , TCF3 cDMR hypomethylation contributes to TCF3 activation.
DNA mutation and methylation in sphingosine signaling
Pathway analysis also showed deregulation of sphingosine-1-phosphate (S1P) signaling in both Burkitt lymphoma and follicular lymphoma when compared to germinal center B cells (Fig. 3a) . S1PR2 (encoding sphingosine-1-phosphate receptor 2) is frequently affected by lossof-function mutations in Burkitt lymphoma and DLBCL, leading to increased AKT and migratory activity 23 . In our analysis, we additionally identified cDMRs in several key pathway genes, including PDGFRB, which is strongly upregulated in both Burkitt lymphoma and follicular lymphoma relative to germinal center B cells (Fig. 3b) ; GNA11 (encoding the stimulatory G q α protein), upregulated in Burkitt lymphoma (Fig. 3c) ; and S1PR1 and GNA12 (encoding a member (Fig. 3d,e) . Analysis of whole-genome sequencing data detected mutually exclusive mutations in several G 12/13 complex genes in 14 of the 21 Burkitt lymphoma samples analyzed (Fig. 3f) . These findings are corroborated by our previous description of RHOA mutations in 8.5% of Burkitt lymphoma samples in an extended cohort of 82 cases 24 and by a recent study functionally implicating G 12/13 complex mutations in the development of germinal center B lymphomas 23 . Interestingly, three of the remaining seven samples were affected by somatic mutations in two genes of the inhibitory G i α complex, GNAI1 and GNAI2, in five Burkitt lymphoma samples, including recurrent (n = 3) GNAI2 mutations encoding p.Arg179His (Fig. 3f) . The G i α complex can regulate several signaling pathways, including the AKT, extracellular signal-regulated kinase (ERK) and protein kinase A (PKA) pathways. Inhibition of PKA in Burkitt lymphoma cell lines did not affect cell viability (Supplementary Fig. 13 ), suggesting that this pathway might not be essential in Burkitt lymphoma; however, mutations of GNAS (encoding the G s α protein) that affected the position homologous to GNAI2 Arg179 are known to cause upregulation of AKT signaling and cell migration in pancreatic adenocarcinoma and pituitary tumors 25, 26 . Recently, it was proposed that, in addition to G 12/13 complex mutations, GNAI2 mutations encoding a p.Arg179His substitution might increase the proliferation and migration of DLBCL cells 27 . Our observations on S1P and G protein signaling suggest that the mutation and differential DNA methylation of genes involved in these pathways might complement each other in suppressing G 12/13 and activating AKT signaling in Burkitt lymphoma.
Differential DNA methylation of transcription factor binding sites
Because cDMRs could be used to identify pathways contributing to the pathogenesis of Burkitt lymphoma through genomic mutation or deregulation by DNA methylation, we sought to identify sets of transcription factors driving the expression of genes with cDMRs. We intersected the cDMR data set with transcription factor binding site data for 46 transcription factors 17, 28 . Significant enrichment (P < 0.05) of transcription factor binding sites was observed for genes that were expressed at lower levels in Burkitt lymphoma than in follicular lymphoma samples and were associated with hypermethylated (Burkitt lymphoma/follicular lymphoma) cDMRs in quadrant 2 of the radar plot (Fig. 4a) . We selected the ten transcription factors displaying the highest correlation of transcription factor and target gene expression (Supplementary Table 11 ) for subsequent analyses. Differential methylation of the corresponding transcription factor binding site typically was restricted to the binding site itself and rapidly returned to background levels outside of this site (Supplementary Fig. 14) .
To understand how cDMR methylation modulates transcription factor target gene expression, we plotted the average methylation levels of cDMRs against average RNA expression of the associated genes for all ten transcription factors (Fig. 4b) . The target genes of STAT5A and BCL3, both enriched in quadrant 2 (Fig. 4a) , displayed hypermethylation and reduced RNA expression in Burkitt lymphoma samples when compared to germinal center B cell and follicular lymphoma samples, in agreement with the low-level activity of the nuclear factor (NF)-κB and JAK-STAT pathways previously reported in Burkitt lymphoma 7 . Similar patterns were observed for the target genes of other transcription factors in quadrant 2. In quadrant 4, we observed hypomethylation and activation of TCF3 target genes in Burkitt lymphoma when compared to follicular lymphoma samples. Germinal center B cell samples displayed intermediate methylation levels, more similar to follicular lymphoma methylation levels than those in Burkitt lymphoma. As previously noted, mutations affecting TCF3 or its negative regulator ID3 detected by us and others 8, 22 in more than two-thirds of all sporadic Burkitt lymphomas have been proposed to foster TCF3-dependent gene expression, driving Burkitt lymphoma cell proliferation 9 . Notably, neither transcription factor nor target gene expression was correlated with cell proliferation differences between Burkitt lymphoma and follicular lymphoma samples (Supplementary Fig. 15 ). Taken together, these findings suggest that both Burkitt lymphoma-and follicular lymphoma-specific gene expression programs are subject to regulation through DNA methylation of transcription factor binding sites.
To assess the impact of the transcription factors on target gene expression at a single-gene level, we generated activity plots integrating and visualizing the correlation of target gene expression with cDMR methylation and the level of transcription factor expression (Fig. 4c) . Individual genes displaying the strongest activation in follicular lymphoma as compared to Burkitt lymphoma included the hallmark gene of follicular lymphomagenesis, BCL2, as well as CBX7, encoding a chromobox protein of Polycomb repressive complex 1 (PRC1) that was previously shown to be functionally involved in lymphomagenesis, with high expression in follicular lymphoma 29 . Notably, strong activation in follicular lymphoma was also observed for a set of genes typically expressed in T cells, including CD3E, CD2, GIMAP1 and ITK, in line with the differential role of bystander T lymphocytes 7 in follicular in contrast to Burkitt lymphomagenesis. TCF3 was among the genes strongly activated in Burkitt lymphoma, in line with the already proposed autoactivation loop regulating its expression (Fig. 4c,d) . Other strongly activated genes included the E2F family member E2F1, the POLD1 gene, which encodes the MYC-interacting DNA polymerase δ 1 , the TERT gene, which encodes telomerase, and the SMARCA4 gene (Fig. 4c,e) encoding a member of the SWI/SNF nucleosome-remodeling complex. Consistent with previous findings 21 , we could independently confirm overexpression of SMARCA4 RNA in Burkitt lymphoma using array-based analysis ( Supplementary Fig. 16 and Supplementary Table 12 ).
DNA mutation and methylation affect SMARCA4 in Burkitt lymphoma
Unexpectedly, the observed strong SMARCA4 transcriptional activation did not result in the upregulation of SMARCA4 target genes in Burkitt lymphoma, despite the fact that SMARCA4 binding sites were hypomethylated (Fig. 4a,f) . These data suggest that suppression of SMARCA4-dependent expression does not occur through hypermethylation of SMARCA4 binding sites in target genes but rather through deregulation by DNA methylation-independent mechanisms in Burkitt lymphoma.
To elucidate the role of SMARCA4 in Burkitt lymphomagenesis, we performed an integrative data analysis (Fig. 5a ) that showed high expression of SMARCA4 in Burkitt lymphoma associated with both decreased DNA methylation and chromatin reprogramming to active promoters (chr. 19: 11.07-11.09 Mb) and enhancers to promoters (chr. 19: 11.15-11.16 Mb). Immunohistochemical staining found strong SMARCA4 protein (BRG1) expression in normal germinal center B cells, but much less pronounced signal was seen in germinal center mantle and other B cell compartments of the tonsils (Fig. 5b  and Supplementary Table 13) ; in contrast, Burkitt lymphoma samples showed ubiquitous, high SMARCA4 protein expression (Fig. 5c  and Supplementary Table 13) .
Whole-genome sequencing of the International Cancer Genome Consortium (ICGC) MMML-Seq cohort identified SMARCA4 mutations in nine of 21 Burkitt lymphoma samples. In line with previous npg reports 30, 31 , these SMARCA4 mutations clustered in the portion of the gene encoding the helicase domain (Fig. 5d) , showing a mutation pattern that stands in strong contrast to the pattern of germline nonsense mutations predisposing to cancer syndromes [32] [33] [34] [35] . Further investigation of the SMARCA4 mutational landscape in bona fide Burkitt lymphoma samples, including data from cell lines and published data, confirmed these observations (Supplementary Table 14) . In the Burkitt lymphoma samples, mutant and wild-type SMARCA4 transcripts had similar expression levels (data not shown), and immunohistochemistry and immunofluorescence analyses of Burkitt lymphoma samples showed constant coexpression of SMARCA4 and MYC proteins in Burkitt lymphoma, regardless of the presence or absence of SMARCA4 mutations (Fig. 5c, Supplementary Fig. 17 and Supplementary Table 13) .
Intriguingly, genomic mutations of other members of the SWI/SNF complex, including ARID1A, ARID1B and SMARCB1, were present A r t i c l e s in a subset of Burkitt lymphoma samples lacking SMARCA4 mutation ( Fig. 5e and Supplementary Table 15) , and, moreover, SWI/SNF complex genes showed increased expression levels in Burkitt lymphoma samples (Fig. 5f) . Protein modeling 36 (Fig. 5g) suggested that SMARCA4 mutations likely do not obstruct binding of the mutant protein to DNA, but some mutations might ablate helicase function directly, through interference with ATP binding, or indirectly, by obstructing the interaction of the helicase N-and C-terminal domains. It has recently been suggested that oncogenic SMARCA4 mutations such as those observed here in Burkitt lymphoma compromise TOP2A chromatin binding, which is dependent on the ATPase activity of SMARCA4.
DNA methylation in lymphomas versus normal B cell development
Finally, we aimed to compare the DNA methylation patterns in Burkitt lymphoma and follicular lymphoma with the DNA methylome changes observed during human B cell differentiation recently described by Kulis et al. 37 . Comparison of the DNA methylation levels determined by WGBS in sorted germinal center B cells in both studies showed excellent agreement (correlation of means = 0.9799; Supplementary Fig. 18a) . Principal-component analysis of the lymphomas analyzed herein together with the recently investigated normal B cell populations showed that the Burkitt lymphoma and follicular lymphoma subsets clustered together but distinctly from the normal B cell subsets (Supplementary Fig. 18b ). This clustering of the follicular lymphomas and Burkitt lymphomas separately from the physiological germinal center B cells most likely relates to the neoplastic process. To further investigate this, we analyzed the differences in DNA methylation separately for Burkitt lymphoma and follicular lymphoma in comparison to normal germinal center B cells for the 20 major modules of dynamic CpG methylation during B cell development defined by Kulis et al. using both WGBS and array-based data (Supplementary Fig. 18c,d ).
In line with what has been described for DLBCL by Kulis et al., we observed strongly increased DNA methylation of CpGs related to Polycomb-repressed regions (modules [17] [18] [19] [20] and decreased DNA methylation of CpGs related to heterochromatin (modules 8 and 9) in both follicular lymphoma and Burkitt lymphoma as compared to germinal center B cells. This analysis extends the previous findings to reflect the fact that Burkitt lymphomas and follicular lymphomas also frequently acquire methylation changes in regions already undergoing dynamic methylation during normal B cell differentiation. Remarkably, when directly comparing the DNA methylation of Burkitt lymphomas and follicular lymphomas for the 20 modules, we hardly observed any differences. This suggests that the DNA methylation differences between these two germinal center B-lymphoma subtypes indeed reflect the separate oncogenic paths driving these lymphomas rather than the DNA methylation dynamics of normal B cell differentiation. The only notable exception was 
npg
A r t i c l e s module 11, which tended to have lower DNA methylation in Burkitt lymphomas than in follicular lymphomas. Remarkably, the CpGs of this module, which are strongly enriched for enhancer sites, are characterized by the fact that they switch their DNA methylation state from the naive B cell to the germinal center B cell stage 37 . This switching, as well as the enrichment for TCF3-binding sites in this module, might to a certain extent relate to the above-described freezing of the functional states of germinal center B cells in Burkitt lymphoma and follicular lymphoma, as well as to the differential activation of oncogenic pathways in these lymphomas (Supplementary Fig. 18e ).
DISCUSSION
The presented DNA methylation analyses of Burkitt lymphoma and follicular lymphoma, both derived from germinal center B cells, identified substantial differences in DNA methylation patterns. By combination with genome and transcriptome analyses, these differences in DNA methylation can be linked to transcription factor activity, and they are critical determinants of follicular lymphoma-and Burkitt lymphoma-specific gene expression patterns. In addition, lymphoma subtype-specific patterns of DNA methylation, integrated with mutation analysis, helped us identify complementary aberrant regulation of the SWI/SNF, TCF3-ID3 and G i α complexes as important contributors to Burkitt lymphomagenesis. Through our integrated analysis, we now add a model for a potential dominant function of mutated SMARCA4 in Burkitt lymphomagenesis (Supplementary Fig. 19 ).
In this model, overexpression of TCF3, initiated by the combination of cDMR hypomethylation and mutation of TCF3 or its inhibitor ID3, leads to high expression of the inactive SMARCA4 protein, which prevents methylation of its binding site and expression of its target genes as a result of maintained binding competence in the absence of helicase activity. 
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METHODS
Methods and any associated references are available in the online version of the paper.
HumanMethylation450k BeadChip methylation analysis. DNA methylation data were processed using GenomeStudio (v2011.1; methylation module 1.9.0) and Qlucore software, applying the default settings.
Whole-genome transcriptome analysis. Transcriptome data were mapped with segemehl 16, 43 , allowing for spliced alignments and using a minimum accuracy of 90%. Differential expression was analyzed using DESeq 45 with default parameters and a significance criterion of 0.05 (P value adjusted for multiple testing).
DMR correlation analysis. cDMRs were identified on the basis of prototypical Burkitt lymphoma (IG-MYC translocation positive; n = 12) and prototypical follicular lymphoma (IG-BCL2 translocation positive and World Health Organization (WHO) grade 1 or 2; n = 8) cases. To obtain DMRs correlating with the expression of nearby genes (DMRs overlapping a gene or at most 1,500 nt upstream of its TSS), no linear relationship was assumed and a Spearman correlation test was performed. GENCODE 46 v14 gene annotation was used for correlation analysis, including protein-coding genes and other biotypes, such as antisense genes, long intergenic noncoding RNAs (lincRNAs), microRNAs and other noncoding genes (Supplementary Table 18 ). DMRs with a significant correlation test (P < 0.05) were declared to be cDMRs.
Control of confounding factors. Control of confounding factors was performed for age bias (Supplementary Fig. 21 ), tumor cell content ( Supplementary Fig. 22 ), proliferation rate as measured by Ki67 expression (Supplementary Figs. 15 and 22) , and homogeneity of DMRs and cDMRs (Supplementary Fig. 23) .
To test the hypothesis that transcription factor expression and transcription factor target gene expression for TCF3, YY1, FOXM1, ZEB1, SMARCA4, STAT5A, PML, BATF and BCL3 are not associated with proliferation status, we pooled all probe sets of the transcription factor genes ( Supplementary  Fig. 15a ) and their targets (Supplementary Fig. 15b ) and correlated them to Ki67 staining, a marker of proliferation, in germinal center DLBCL (GCB DLBCL; n = 160). In both cases, no meaningful correlation (Spearman correlation = 0.02 and 0.043, respectively) was found. To analyze whether a subset of the transcription factor genes or their targets are associated with proliferation status, we additionally carried out clustering analysis ( Supplementary  Fig. 15c-f) . In both supervised and unsupervised clustering, we found no such association.
Transcription factor binding site enrichment analysis. For all binding sites of each transcription factor annotated in GM12878 (refs. 46-48), we checked whether they were significantly enriched in one of the four classes of cDMRs.
If available, replicates were merged. For significance testing, bootstrapping was used. As a background model for this test, we used the set of all prototypical Burkitt lymphoma and follicular lymphoma DMRs that were associated with a gene, including noncorrelating DMRs.
Activity plots. For each cDMR-gene pair, an activation score y (where y = ρ × log 2 (fold change)) was calculated, where ρ was the Spearman correlation coefficient of the cDMR-gene pair. These activation scores were assigned to transcription factors with a binding site in the cDMR. For transcription factors with more than one binding site in different cDMRs belonging to the same gene, the average of the activation scores was used. The activation scores for the top 40 transcription factor-gene pairs were plotted using the gplots package in R (3.1.0) 44 .
Correlation tests, tests for equality of groups and box plots. To increase robustness and to avoid the violation of assumptions (for example, variance homogeneity and normal distribution), non-parametric tests were used throughout this study. For all correlations, we used Spearman's rank correlation method. The equality of the distributions of mean methylation values between the groups (Fig. 1b) was tested using a two-tailed non-parametric WilcoxonMann-Whitney test. The upper and lower 'hinges' of all box plots correspond to 25th and 75th percentiles. The whiskers extend from the hinge to the highest or lowest value that is within the 1.5-fold interquartile range of the hinge. Data falling beyond the whiskers are outliers and are plotted as points.
ChIP segmentation for the BL-2, DG-75 and KARPAS-422 cell lines. Reads were mapped to a sex-matched reference (GRCh37) using BWA 0.5.9, with the read trimming parameter (-q) set to 15. Alignments were sorted and duplicates were marked with Picard. Mappings with a MAPQ score below 15 were filtered out with SAMtools.
We segmented the DG-75, BL-2 and KARPAS-422 cell line genomes with the ChIP-seq data for the six histone modifications described above. For this purpose, we used the implementation described by Ernst et al. 49 in ChromHMM software (v1.03). The input data were ChIP-seq BED files with the genomic coordinates and strand orientation of mapped sequences (after removing duplicate reads). The genome was divided into consecutive 200-bp non-overlapping intervals, each of which was independently assigned a notation of present (1) or absent (0) for each of the six chromatin modifications. Assignment was based on the count of tags mapping to the interval and on the Poisson background model using a threshold of 1 × 10 −4 , as explained in Ernst et al. After binarization and for segmentation, we used the 11-state model established by the BLUEPRINT Consortium. Further, we computed the probability that each location was in a given chromatin state and then assigned each 200-bp interval to its most likely state for each sample. Lastly, consecutive intervals in the same chromatin state were joined. SMARCA4 modeling. The structure of the N-terminal helicase domain (DEXDc) and conserved C-terminal helicase domain of human SMARCA4 (residues Gln756 to Val1224) interacting with double-stranded DNA (dsDNA) was modeled on the structure of the Sulfolobus solfataricus SWI2/SNF2 ATPase core in complex with dsDNA 50 using Modeller 51 . This structure was superposed on the structure of Mycobacterium tuberculosis SecA 52 bound to ADP, to position ADP in the final SMARCA4-dsDNA-ADP model shown in Figure 5g .
Array-based gene expression analysis. For the MMML cohort comprising 935 samples, including primary lymphomas, lymphoma cell lines and normal B cell controls, array-based gene expression data from Affymetrix GeneChip U133A arrays were available. Data from all gene expression arrays were jointly normalized with the variance-stabilizing normalization (VSN) method 53 as described previously 21 . On the basis of gene expression, a 'molecular Burkitt lymphoma (mBL) index' (ref. 21 ) was calculated for each individual sample and was assigned one of the following molecular diagnoses; mBL (index score ≥ 0.95), non-mBL (index score ≤ 0.05) or molecular intermediate (remaining cases) 21 . The lymphomas were also stratified according to their 'pathway activation patterns' (ref. 54 ). The cell of origin was classified according to the methods described by Wright et al. 42 using a modified classifier 21 .
To characterize the expression landscape of specific gene sets in lymphoma subgroups, the samples were classified in two ways. First, cell lines (n = 32) were compared with lymphomas classified as mBL (n = 84) 21 and follicular lymphomas (n = 144). DLBCLs were subdivided into activated B cell (ABC; n = 106), germinal center B cell (GCB; n = 176) and unclassified (n = 80) subtypes 55 . Tonsil samples (n = 10), naive B cells (n = 8), germinal center B cells (n = 13) and post-germinal center B cells (n = 9) were used as normal controls.
In a second, more stringent approach, lymphomas with the mBL signature 21 , the Burkitt lymphoma pathway activation pattern 54 and IG-MYC translocation and without HIV infection were classified as prototypical Burkitt lymphomas (n = 58). Lymphomas with a diagnosis of follicular lymphoma grade 1 or 2, with t(14;18) translocation and without DLBCL components were classified as prototypical follicular lymphomas (n = 75). Germinal center B cell controls did not have Epstein-Barr virus (EBV) infection (n = 10).
